NCT05918302 2026-03-06
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
Clinical Trials
17 trialsNCT07407517 2026-02-12
POLARIS
Fudan University
Phase 3 Not yet recruiting
NCT05476939 2026-02-05
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT00799188 2025-12-19
CERTICOEUR
Hospices Civils de Lyon
Phase 3 Completed
NCT01805271 2025-05-14
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
UNICANCER
Phase 3 Active not recruiting
NCT02246127 2025-05-11
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Completed
NCT03839940 2025-01-29
MIST
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT05954442 2024-01-16
BCTOP-T-M03
Fudan University
Phase 3 Recruiting
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT02511639 2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3 Completed
NCT01248403 2020-01-29
AIO-STO-0111
Krankenhaus Nordwest
Phase 3 Completed
NCT02376985 2019-10-21
Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT
Comprehensive Support Project for Oncology Research
Phase 3 Completed
NCT02134899 2018-12-10
EVERKYSTE
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT03580239 2018-07-09
Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency
Tianjin Medical University Second Hospital
Phase 3 Unknown
NCT02404051 2016-06-15
FEVEX
Consorzio Oncotech
Phase 3 Unknown
NCT00567554 2016-02-10
GeparQuinto
GBG Forschungs GmbH
Phase 3 Completed
NCT01773460 2016-02-10
Evelyn
GBG Forschungs GmbH
Phase 3 Terminated